Background {#Sec1}
==========

Among squamous cell carcinomas (SCC) originating in the upper aerodigestive tract, the management of hypopharyngeal squamous cell carcinoma (HPSCC) remains to be one of the most challenging and controversial topics, due to the poor survival rate and potentially devastating effects on speech and swallowing \[[@CR1]\]. Alcohol consumption and acetaldehyde, a toxic product of ethanol metabolism, are widely known as carcinogen of head and neck SCC (HNSCC) and esophageal SCC (ESCC). The activity of *aldehyde dehydrogenase 2*, a key enzyme in the elimination of aldehyde, is reduced by the germline polymorphism Glu504Lys (previously described as Glu487Lys), which is prevalent in Mongoloid but not in Caucasoid or Negroid populations \[[@CR2]\]. Therefore, this different genetic background is considered as a major reason of high HPSCC and ESCC incidence rates in East Asia \[[@CR3], [@CR4]\].

Tumor suppressor gene *TP53* is the most frequently mutated gene in human cancers: more than 50% of human cancers contain somatic mutations in this gene \[[@CR5], [@CR6]\]. Tumor suppressor p53, encoded by the *TP53* gene, is a key protein involved in many cellular anticarcinogenic processes such as apoptosis and cell-cycle control \[[@CR7]\]; therefore, p53 is widely known as the guardian of the genome \[[@CR8]\]. Molecular alterations in carcinogenesis of HNSCC include loss of p53 function, which is mediated by genetic mechanisms such as *TP53* mutations \[[@CR9]\] and loss of heterozygosity \[[@CR10]\], or degradation of p53 meditated by the human papillomavirus (HPV) oncoprotein E6 \[[@CR11]\].

Two studies previously demonstrated the association between *TP53* mutations and prognosis in surgically treated HNSCC patients. \[[@CR12], [@CR13]\] However, these studies did not examine these associations based on the anatomical location of the HNSCCs. Moreover, patients with oropharyngeal SCC (OPSCC) comprised the majority of the cases, and there were a total of only two patients with HPSCC in the two studies. HPV-related OPSCCs commonly express wild type *TP53* \[[@CR14]\], creating a potential confounder as HPV-related tumors have a generally favorable prognosis. In contrast, HPV-driven HPSCC is considered rare \[[@CR15]\] and the prognostic significance of *TP53* mutation status in HPSCC has not yet been investigated. The aim of this study was to evaluate the prognostic significance of *TP53* mutation status among surgically treated HPSCC patients in Japan, where the HPSCC incidence rate is high.

Methods {#Sec2}
=======

We retrospectively reviewed the clinical charts of HPSCC patients, who had been surgically treated between 2008 and 2014 at the University of Tokyo Hospital. We excluded patients, who underwent salvage surgery after the definitive radiotherapy (RT) or chemoradiotherapy (CRT), and those who received preoperative chemotherapy. We identified 57 HPSCC patients (55 men and 2 women; age range: 46--84 years, median age: 68 years) who underwent initial surgery of primary lesions. Subsites of primary tumor were the pyriform sinus, posterior wall, and postcricoid region, in 37 (65%), 15 (26%), and 5 (9%) patients, respectively. TNM staging was done according to the 7th edition of the Union for International Cancer Control (2009) staging guidelines. The indication for postoperative RT/CRT was comprehensively determined on the basis of the clinicopathological status of the patients including impaired performance status, inadequate surgical margin, ≥4 metastatic LNs, presence of extranodal extension (ENE), and postoperative complications as well as the consent of patient. The Institutional Review Board of the University of Tokyo Hospital approved this study (\#2487 and \#2904).

Determination of human papillomavirus status {#Sec3}
--------------------------------------------

In OPSCC, p16 immunopositivity is commonly used as a surrogate marker for HPV determination \[[@CR16]\]. Therefore, the p16 status was evaluated in surgically excised specimens using immunohistochemistry (IHC) according to the standard techniques as previously described \[[@CR17]\]. A mouse p16 monoclonal antibody (1:100 dilution; Santa Cruz Biotechnology, CA, USA) was used as the primary antibody, and immunostained samples were blindly reviewed and scored independently by two investigators (M. A and Y. S). In accordance with previous studies, p16 positivity by IHC was defined as strong and diffuse nuclear and cytoplasmic staining in ≥70% of the tumor cells \[[@CR16], [@CR17]\].

However, p16 expression does not always indicate the presence of HPV DNA, and the combination of p16 expression determined by IHC with HPV DNA determination by polymerase chain reaction (PCR) or in situ hybridization (ISH) is considered to provide the almost perfect sensitivity and specificity \[[@CR18], [@CR19]\]. Therefore, p16-immunopositive specimens were also tested for HPV DNA by HPV-ISH, as previously described \[[@CR19], [@CR20]\]. Briefly, HPV DNA was detected using an ISH method with catalyzed signal amplification (GenPoint signal amplification system; Dako, Kyoto, Japan), in accordance with the manufacturer's instructions. Slides were hybridized using a biotinylated GenPoint HPV probe (This probe has been found to react with HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 on FFPE tissues and/or cells by ISH, Dako). Slides were scored as positive for HPV if a punctate signal pattern was observed in almost all tumor nuclei.

Genomic DNA extraction {#Sec4}
----------------------

Tumor tissue specimens were collected during surgery, and snap-frozen in liquid nitrogen and stored at −80 °C. Genomic DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), in accordance with the manufacturer's protocol. In specimens where the harvest of frozen sections appeared to interfere with the pathological margins, DNA was isolated from formalin-fixed, paraffin-embedded (FFPE) tissue blocks. Briefly, the tumor lesions on hematoxylin and eosin-stained slides were marked, and the corresponding areas were identified on unstained tissue sections. Each selected area was carefully dissected under microscopic observation. Genomic DNA was then extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen).

Detection of *TP53* mutations {#Sec5}
-----------------------------

PCR amplification and Sanger sequencing were performed to detect *TP53* mutations in exons 2--9, containing 98% of all mutations described in HNSCC cases \[[@CR21]\]. A total of 20 ng/μl genomic DNA per sample was used for PCR amplification using PrimeSTAR HS DNA Polymerase(Takara Bio, Shiga, Japan). Amplification conditions included two-step cycle of 98 °C for 15 s and 68 °C for 90 s, for a total of 44 cycles, except for the amplification of exon 2--3 fragments harvested from frozen and FFPE specimens and exon 6 fragments harvested from FFPE specimens, which were amplified by nested PCR (25 cycles each) using two primer pairs. Subsequently, PCR products harvested from FFPE tissue were purified using the QIAquick PCR Purification Kit (Qiagen), in accordance with the manufacturer's protocol. Mutations were confirmed by Sanger sequencing using the Big Dye Terminator v3.1 Cycle Sequencing Kit and 3130xL Genetic Analyzer (Applied Biosystems, CA, USA). In this study, nonsense mutations, splice variants, and frameshifts were defined as truncating mutations, that lead to nonfunctional p53, based on previous studies \[[@CR13], [@CR22]\]. All samples were sequenced twice with independent PCR using forward and reverse primers.

Immunohistochemistry for p53 expression {#Sec6}
---------------------------------------

IHC for p53 expression was performed according to standard IHC techniques. A mouse p53 monoclonal antibody clone DO-7 (1:100 dilution; Leica Biosystems, Nussloch, Germany) was used as the primary antibody. In accordance with a previous study, a sample was determined as p53-immunopositive when ≥10% of tumor nuclei were immunostained \[[@CR23]\].

Statistical analyses {#Sec7}
--------------------

Primary endpoint was disease-specific survival (DSS) and secondary endpoint was overall survival (OS). Potential correlations between the treatment method and several clinical features were evaluated using the chi-square test; for analyses in which there were \<4 patients, the Fisher's exact test was used. Survival was analyzed using the Kaplan--Meier method and the log-rank test. Variables were also analyzed by multivariate survival analysis using the Cox proportional hazards model. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated to determine the effect of each variable on outcomes. *P* values \<0.05 were considered statistically significant. GraphPad Prism software version 5 (GraphPad Software, CA, USA) was used for the chi-square, Fisher's exact, Mann-Whitney's *U*, and log-rank tests. Mac Tahenryo-Kaiseki version 2.0 (ESUMI, Tokyo, Japan) was used for multivariate Cox regression models.

Results {#Sec8}
=======

Human papillomavirus status of patients with hypopharyngeal squamous cell carcinoma {#Sec9}
-----------------------------------------------------------------------------------

In this cohort of 57 HPSCC patients, 3 (5%) patients were immunopositive for p16; however, none of these three patients had detectable HPV DNA by HPV-ISH. Therefore, HPSCC was confirmed to be unrelated to HPV in all patients in this study (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1The representative case of p16-immunopositive tumor. **a** p16 immunostaining, and **b** HPV-ISH analysis of the identical tumor. None of p16-immunopositive tumor in our HPSCC cohort was positive by HPV-ISH (original magnification × 100)

Distribution of *TP53* mutations {#Sec10}
--------------------------------

*TP53* mutations were detected in 39 (68%) patients. Missense mutations, nonsense mutations, splicing variants, and frameshift mutations were found in 24 (42%), 9 (16%), 4 (7%), and 2 (3%) patients, respectively. *TP53* mutations in exon 2, 3, 4, 5, 6, 7, 8, and 9 were found in 1, 0, 3, 11, 9, 4, 8, and 3 patients, respectively (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Distribution of *TP53* mutations according to the affected exons. Exon 2, 3, 4, 5, 6, 7, 8, and 9 of *TP53* mutations were found in 1, 0, 3, 11, 9, 4, 8, and 3 patients, respectively

Clinicopathological features and *TP53* mutation status {#Sec11}
-------------------------------------------------------

Table [1](#Tab1){ref-type="table"} summarizes the clinical data and *TP53* status. Table [2](#Tab2){ref-type="table"} shows the clinicopathological features according to *TP53* mutation status. Histopathological analysis revealed positive surgical margins in 11 (19%) patients, ≥4 metastatic LNs in 14 (25%) patients, and ENE in 15 (26%) patients. Postoperative RT/CRT was administered to 16 (28%) patients. Of note, all of stage I/II patients (5 patients) had wild-type *TP53*, and patients with a past history of HNSCC or ESCC were significantly greater in the *TP53* mutation groups than in the wild-type groups (*P* = 0.02). Administration of postoperative RT/CRT did not correlate with *TP53* mutation status (*P* = 0.25).Table 1Clinical data and *TP53* statusAge, genderTN*TP53*p53-IHCNo. of LNsTumor differentiationMarginsENEFollow-up periods (months)62 MT3N2btruncating--2M+--101NED73 MT3N2bwt+9M+--85DOC78 MT3 N0truncating--0M----11DOD49 MT2 N0wt+0W----94NED72 MT3 N1missense+2W----36DOC65 MT3N2bmissense+3M--+27NED68 MT2N2bwt--11W----92NED67 MT3N2btruncating--5M+--11DOD81 MT3 N1wt--3W----66NED80 MT3N2btruncating--3M--+17DOD64 MT1N2btruncating--2W--+82NED79 MT3 N0missense--0M----66NED81 MT3N2btruncating--2M--+24DOD66 MT4aN0truncating--0M----76NED81 MT3 N0missense+0W----4DOC62 MT2 N0wt--1P----75NED83 MT1 N0wt--0P+--41DOD70 MT3N2btruncating--14M--+11DOD75 MT2N2bwt+2M+--55NED55 MT4aN2bmissense+4W--+24DOD46 MT4aN0missense+0M----66DOC55 MT4aN2bmissense--6W----12NED71 MT3N2cmissense+25M--+17DOD79 MT4aN0missense+1M----7DOD63 MT3 N0missense--2M----29DOD67 MT2 N0wt--0W----60NED61 MT4aN2bmissense+4W++5DOD84 MT4aN0truncating--0M----8DOD60 MT4aN2ctruncating--12P----9.2DOC68 MT3 N0truncating--0M----55NED60 MT1 N0wt--0M----53NED67 MT4aN0wt--4W----50NED72FT3 N0missense+0M----27NED72 MT3 N0missense--0M----49NED81 MT3 N1wt--3W----17DOD72 MT3 N1missense+1M----49NED84 MT3 N0missense+2M+--5DOD47 MT3 N0wt--0W----23DOC69 MT1N2amissense--2W++6DOD64FT3N2cmissense+3M----14DOD69 MT3 N1missense--2W--+45NED64 MT3 N0missense+0M+--43NED63 MT3 N1truncating--3M----41NED76 MT3 N0wt+1M--+37NED71 MT4aN2bmissense+1M--+16DOC75 MT3N2bmissense--3M--+37NED67 MT4aN2bwt--4M----36NED74 MT3 N0wt--3P----42NED82 MT4aN2bmissense+1M----32NED52 MT3N2cwt+3M--+32NED64 MT4aN0missense+0P----24DOC48 MT4aN2btruncating--4W----30NED71 MT4aN0wt--3M+--28NED64 MT4aN2btruncating--2M--+17DOD84 MT3N2btruncating--14M----16DOD64 MT3 N1missense+1M+--25NED79 MT4aN1wt--1W----24NED*IHC* immunohistochemistory, *No. LNs* the number of metastatic lymph nodes, *ENE* extranodal extension, *M* male, *F* female, *W* well differentiated, *M* moderately differentiated, *P* poorly differentiated, *NED* no evidence of disease, *DOD* died of the disease, *DOC* died of other cause Table 2Clinicopathological parameters according to *TP53* mutation statusClinicopathological featuresTotal (*n* = 57)*TP53* status*P* valueWild-type (*n* = 18)Mutation (*n* = 39)AgeRange (median)47--83 (70)46--84 (68)0.45\*\*SubsitesPS2712150.25PC505PW1569TT1--34014260.30\*T417413NN0/13213190.15N2/325520StageI/II5500.002\*III/IV521339Tumor differentiationW./M. SCC5215370.31\*P. SCC532MarginNegative4614320.73Positive1147No. of metastatic LNs≤34314291.00≥414410ENEAbsent4216260.11\*Present15213PORT/CRTAbsent4114270.25Present16412Anamnestic SCCAbsent4217250.02\*Present15114*PS* pyriform sinus, *PC* postcricoid, *PW* posterior wall, *T* tumor classification, *N* nodal classification, *Stage* stage classification, *W* well differentiated, *M* moderately differentiated, *P* poorly differentiated, *SCC* squamous cell carcinoma, *No* number, *LN* lymph node, *ENE* extranodal extension, *PORT/CRT* postoperative radiotherapy/chemoradiotherapy, *Anamnestic SCC* anamnestic squamous cell carcinoma arising from esophagus and head and neck region, \*: Fisher's exact tests were used. \*\*: Mann-Whitney's U test was used

Association between *TP53* mutation and p53 expression {#Sec12}
------------------------------------------------------

Representative images of specimens exhibiting p53 immunopositivity are presented in Fig. [3](#Fig3){ref-type="fig"}. p53 immunopositivity was detected in 22 patients, including 5 (28%) and 17 (71%) patients in the wild-type and missense mutation groups, whereas there were no patients with p53 immunopositivity in the truncating mutation group (*P* = 0.0001, chi-square test).Fig. 3Representative images of p53-immunopositive tumor (original magnification × 100)

Correlation between *TP53* mutation status and prognosis {#Sec13}
--------------------------------------------------------

Eighteen (32%) patients died from HPSCC, whereas 8 (14%) patients died from other causes. The remaining 31 (54%) patients were alive and disease-free on last follow-up date. The median follow-up period for the entire cohort was 29 months (range: 3.5--101 months), whereas 45 months (range: 24--101 months) for patients who survived (*n* = 31) and 16 months (range: 3.5--85 months) for those who died (*n* = 26). The 3-year DSS of the wild-type group was significantly longer than that of the *TP53* mutation group (94% vs 55%; *P* = 0.01, Fig. [4](#Fig4){ref-type="fig"}). Furthermore, patients with wild-type/missense mutations had significantly better 3-year DSS than those with truncating mutations (76% vs 43%; *P* = 0.03). The 3-year DSS rate of wild-type, missense mutation, and truncating mutation groups were 94%, 61%, and 43%, respectively (Fig. [5](#Fig5){ref-type="fig"}). The 3-year OS of the wild-type group was significantly longer than that of the *TP53* mutation group (89% vs 42%; *P* = 0.007). The 3-year OS rate of wild-type/missense mutation group was not significantly different than that of the truncating mutation group (66% vs 40%; *P* = 0.14). The 3-year OS rate of the wild-type, missense mutation, and truncating mutation group were 89%, 43%, and 40%, respectively. In contrast, p53 immunopositivity did not correlate with DSS (*P* = 0.77). In the subgroup analyses of 52 stage III/IV patients, the 3-year DSS of the wild-type group was significantly longer than that of the *TP53* mutation group (92% vs 55%; *P* = 0.02). The 3-year OS of the wild-type group was significantly longer than that of the *TP53* mutation group (92% vs 42%; *P* = 0.006).Fig. 4Disease-Specific Survival (DSS) according to the presence of *TP53* mutation. The 3-year DSS rate of patients with wild-type *TP53* was significantly longer than that of patients with *TP53* mutations (94% vs 55%, *P* = 0.01) Fig. 5Disease-Specific Survival (DSS) according to the *TP53* mutation status. The 3-year DSS rate of the patients with wild-type *TP53*, missense *TP53* mutation, and truncating *TP53* mutation were 94%, 61%, and 43%, respectively

Table [3](#Tab3){ref-type="table"} shows the associations between the clinicopathological factors and DSS in univariate analysis. The presence of ≥4 metastatic LNs (*P* = 0.04) and ENE (*P* = 0.03) were poor prognostic factors. In contrast, tumor differentiation grade, T classification, stage, surgical margin, and postoperative RT/CRT did not correlate with DSS.Table 3Univariate analyses for disease-specific survivalVariablesHR (95% CI)*P* valueTumor differentiationW./M. vs. P.SCC0.63 \[0.13--3.09\]0.57T classificationT1--3 vs. T41.12 \[0.39--3.25\]0.83StageStage I/II vs. III/IV2.30 \[0.55--9.56\]0.25MarginNegative vs. Positive2.08 \[0.61--7.07\]0.24No. of metastatic LNs≤3 vs. ≥43.34 \[1.04--10.7\]0.04ENEAbsent vs. Present3.34 \[1.11--10.1\]0.03PORT/CRTPerformed vs. Not performed0.91 \[0.33--2.53\]0.86*TP53* mutationWild-type vs. Mutation3.32 \[1.28--8.60\]0.01p53 immunopositivityNegative vs. Positive0.87 \[0.33--2.27\]0.77*HR* hazard ratio, *95% CI* 95% confidence interval, *W* well differentiated, *M* moderately differentiated, *P* poorly differentiated, *SCC* squamous cell carcinoma, *T* tumor classification, *No* number, *LN* lymph node, *ENE* extranodal extension, *PORT/CRT* postoperative radiotherapy/chemoradiotherapy

Multivariate Cox proportional hazard analysis using variables based on univariate analyses was conducted to determine independent prognostic factors for DSS and OS. The presence of *TP53* mutations (*P* = 0.04; HR, 4.96; 95% CI, 1.08--22.8, and *P* = 0.02; HR, 4.75; 95% CI, 1.35--16.7, respectively) and ≥4 metastatic LNs (*P* = 0.03; HR, 3.00; 95% CI, 1.12--8.04, and *P* = 0.02; HR, 2.89; 95% CI, 1.22--6.86, respectively) have significant adverse effects on both DSS and OS. In the subgroup analyses of 52 stage III/IV patients, the presence of *TP53* mutations was a significant adverse prognostic factor on OS, and nearly reached significance on DSS. (Table [4](#Tab4){ref-type="table"}).Table 4Multivariate analyses for disease-specific and overall survivalVariablesOverall (*n* = 57)Stage III/IV (*n* = 52)DSSOSDSSOSHR \[95% CI\]*P* valueHR \[95% CI\]*P* valueHR \[95% CI\]*P* valueHR \[95% CI\]*P* value*TP53*Wild-type vs. Mutation4.96 \[1.08--22.8\]0.044.75 \[1.35--16.7\]0.027.72 \[0.98--60.7\]0.055.51 \[1.24--24.5\]0.03No. of metastatic LNs≤3 vs. ≥43.00 \[1.12--8.04\]0.032.89 \[1.22--6.86\]0.023.07 \[1.13--8.35\]0.032.89 \[1.20--6.94\]0.02ENEAbsence vs. Presence1.85 \[0.70--4.86\]0.211.39 \[0.59--3.27\]0.451.81 \[0.68--4.80\]0.231.36 \[0.58--3.21\]0.48*DSS* disease-specific survival, *OS* overall survival, *HR* hazard ratio, *95% CI* 95% confidence interval, *No* the number, *ENE* extranodal extensio

Discussion {#Sec14}
==========

In this retrospective study, we demonstrated that the *TP53* mutation status significantly correlated with poor prognosis in surgically treated HPSCC patients. Specifically, patients with truncating mutations exhibited the worst prognosis. To the best of our knowledge, this is the first study focusing on the association between *TP53* mutation status and prognosis of HPV-unrelated HPSCC. The result of the current study was consistent with the previous studies investigating all HNSCC subsites \[[@CR12], [@CR13]\], which included patients with HPV-driven OPSCC.

HPSCC is rarely caused by HPV-driven carcinogenesis as we confirmed in the current study and occurs more frequently in East Asian population than in other regions of the world. Survival of patients with HPSCC has not markedly improved in recent decades. In the last two-decades, CRT and induction chemotherapy followed by RT have become the option for advanced HNSCC patients who prefer nonsurgical organ preservation \[[@CR24]--[@CR26]\]. However, RT-induced late toxicity, such as dysphasia and osteonecrosis distresses emerging issues for cancer survivors. The recent development of minimally invasive surgical procedures, such as transoral robotic surgery (TORS) and transoral videolaryngoscopic surgery (TOVS) techniques, has broadened surgical indications and appeared to result in better outcomes with respect to the postoperative speech and swallowing function \[[@CR27], [@CR28]\]. Therefore, surgery remains the main treatment modality for HPSCC patients. Our multivariate analyses revealed that both the *TP53* mutation status and the presence of ≥4 metastatic LNs were independent adverse prognostic factors for surgically treated HPSCC patients. In the previous study, we demonstrated that the presence of multiple metastatic LNs was significantly associated with the poor prognosis and the incidence of distant metastases in advanced HPSCC patients treated with total pharyngolaryngectomy \[[@CR29]\]. Collectively, *TP53* mutations can be a useful biomarker for HPSCC patients, in addition to the traditional metastatic LN number.

Interestingly, the past history of HNSCC or ESCC was significantly higher in the *TP53* mutation group than in the wild-type group in the present study. HNSCC and ESCC have been known to occur synchronously or metachronously, which might be explained by the concept of "field cancerization" first introduced by Slaughter et al. in 1953 \[[@CR30]\]. Currently, repetitive exposure to acetaldehyde is considered to play a key role in field cancerization of the squamous epithelium in the head and neck region and the esophagus \[[@CR31]\]. Moreover, Waridel et al. reported that mutations in *TP53* were frequent and early events in the pathogenesis of HNSCC and identified the expansion of multiple clones of mutant p53-containing cells as an important biological step in field cancerization \[[@CR32]\]. Our findings in the current study led further support to these observations. Future studies with larger sample size and longitudinal evaluations, supported with basic research, are necessary to confirm this hypothesis.

In the current study, we demonstrated that p53 immunopositivity was observed most frequently in the presence of missense mutations. Wild-type p53 protein is rapidly degraded via the ubiquitin-proteasome system, resulting in low p53 protein expression. Conversely, the nonsense-mediated RNA decay and the resultant decreased amount of the protein considered to be the reason why truncating p53 proteins cannot be detected by IHC \[[@CR33]\]. Some missense mutations, that result in increased p53 immunopositivity can lead to a dominant-negative or a gain-of-function phenotype \[[@CR34], [@CR35]\], Our observations in the current study support these biological mechanisms; therefore, the distinction between missense and truncating mutations is reasonable for the clinical categorization of the *TP53* mutation status.

The Cancer Genome Atlas (TCGA) reported that *TP53* mutations were detected in 84% of HPV-unrelated HNSCC cases using whole-exome sequencing analysis \[[@CR14]\]. In comparison, the frequency of *TP53* mutations was lower in the HPSCC cohort of the current study, which might be partially due to differences in racial composition and tumor subsites. The HNSCC cohort of TCGA consisted almost entirely of Caucasoid and Negroid populations, with only two HPSCC patients. Additionally, it is possible that mutation detection sensitivity of whole-exome sequencing was superior to that of Sanger sequencing.

To improve the prognoses of HPSCC patients with *TP53* mutations, adjuvant therapy should be selectively administered to these patients. *TP53* mutation, however, is also known as a predictive marker for chemo- and radioresistance in HNSCCs. \[[@CR36], [@CR37]\] Therefore, it might be unreasonable to use *TP53* mutation status as a therapeutic biomarker for existing postoperative treatments including RT/CRT. Although most of the current targeted therapies are inhibitors of oncogenic pathways, development of p53-targeted therapy is warranted.

One of the limitations of our study was a lack of detailed comparison and functional study of each *TP53* mutations, due to the small sample size. In line with previous reports on HNSCC \[[@CR13]\], various mutation types were detected in various regions of *TP53* genes. Further investigation with larger sample size is required to elucidate the potential associations between the mutations with respect to functional and biological effects and prognosis. Furthermore, the number of T1--2 tumors was small in this study. Recently, TORS and TOVS techniques for T1--2 tumors to which RT/CRT was previously preferable were broadened. Therefore, further accumulation of T1--2 patients is also required.

Conclusions {#Sec15}
===========

We demonstrated that *TP53* mutations had a significant impact on prognosis, in surgically treated HPSCC patients. In particular, truncating mutations which were not detected by p53 IHC were shown to have predictive value for a worst survival. Further confirmation from prospective studies with larger sample size including more T1--2 patients is warranted.
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